PMID- 8621762
OWN - NLM
STAT- MEDLINE
DCOM- 19960614
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 97
IP  - 8
DP  - 1996 Apr 15
TI  - Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely 
      infected human cells. Evidence for a transcriptional block.
PG  - 1795-803
AB  - Cyclopentenone prostaglandins (PGs) inhibit virus replication in several DNA and 
      RNA virus models, in vitro and in vivo. In the present report we demonstrate that 
      the cyclopentenone prostaglandins PGA(1) and PGJ(2) at nontoxic concentrations 
      can dramatically suppress HIV-1 replication during acute infection in CEM-SS 
      cells. PGs did not affect HIV-1 adsorption, penetration, reverse transcriptase 
      activity nor viral DNA accumulation in HIV-1 infected cells. A dramatic reduction 
      in HIV-1 mRNA levels was detected up to 48-72 h after infection (p.i.) in 
      PG-treated cells, and HIV-1 protein synthesis was greatly reduced by a single 
      PG-treatment up to 96 h p.i. Repeated PGA(1)-treatments were effective in 
      protecting CEM-SS cells by the cytopathic effect of the virus, and in 
      dramatically reducing HIV-1 RNA levels up to 7 d after infection. The antiviral 
      effect was not mediated by alterations in the expression of alpha-, beta-, or 
      gamma-interferon,TNFalpha, TNFbeta, IL6, and IL10 in HIV-infected CEM-SS cells. 
      The fact that prostaglandins are used clinically in the treatment of several 
      diseases, suggests a potential use of cyclopentenone PGs in the treatment of 
      HIV-infection.
FAU - Rozera, C
AU  - Rozera C
AD  - Laboratory of Virology, Rome, Italy.
FAU - Carattoli, A
AU  - Carattoli A
FAU - De Marco, A
AU  - De Marco A
FAU - Amici, C
AU  - Amici C
FAU - Giorgi, C
AU  - Giorgi C
FAU - Santoro, M G
AU  - Santoro MG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Interleukins)
RN  - 0 (Lymphotoxin-alpha)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (Prostaglandins A)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (RNA, Viral)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 60203-57-8 (9-deoxy-delta-9-prostaglandin D2)
RN  - 9008-11-1 (Interferons)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - EC 2.7.7.49 (RNA-Directed DNA Polymerase)
RN  - RXY07S6CZ2 (Prostaglandin D2)
RN  - VYR271N44P (prostaglandin A1)
SB  - IM
MH  - Antiviral Agents/*pharmacology
MH  - Base Sequence
MH  - Cell Division/drug effects
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - DNA, Neoplasm/biosynthesis/drug effects
MH  - Gene Expression/drug effects
MH  - HIV Reverse Transcriptase
MH  - HIV-1/*drug effects/physiology
MH  - Humans
MH  - Interferons/biosynthesis
MH  - Interleukins/biosynthesis
MH  - Lymphotoxin-alpha/biosynthesis
MH  - Molecular Sequence Data
MH  - Neoplasm Proteins/biosynthesis/drug effects
MH  - Oligonucleotides, Antisense/pharmacology
MH  - Prostaglandin D2/*analogs & derivatives/pharmacology
MH  - Prostaglandins A/*pharmacology
MH  - RNA, Neoplasm/biosynthesis/drug effects
MH  - RNA, Viral/biosynthesis/drug effects
MH  - RNA-Directed DNA Polymerase/metabolism
MH  - T-Lymphocytes
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/biosynthesis
MH  - Virus Replication/*drug effects
PMC - PMC507247
EDAT- 1996/04/15 00:00
MHDA- 1996/04/15 00:01
PMCR- 1996/04/15
CRDT- 1996/04/15 00:00
PHST- 1996/04/15 00:00 [pubmed]
PHST- 1996/04/15 00:01 [medline]
PHST- 1996/04/15 00:00 [entrez]
PHST- 1996/04/15 00:00 [pmc-release]
AID - 10.1172/JCI118609 [doi]
PST - ppublish
SO  - J Clin Invest. 1996 Apr 15;97(8):1795-803. doi: 10.1172/JCI118609.